Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Role of P2 × 7 receptor in the differentiation of bone marrow stromal cells into osteoblasts and adipocytes.

Li W., Li G., Zhang Y., Wei S., Song M., Wang W.

Animal Study on Hip, published in Exp Cell Res (2015) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Exp Cell Res (2015)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
26481422
DOI
10.1016/j.yexcr.2015.10.011

Abstract (original English)

Imbalance in osteogenesis and adipogenesis of bone marrow stromal cells is a crucial pathological process of osteoporosis. P2 × 7-deficient mice were previously shown to exhibit an osteopenic phenotype and abnormal fat distribution, leading us to hypothesize that P2 × 7R activation was involved in the differentiation of BMSCs. Consequently, we investigated the effect of P2 × 7R activation on osteogenic and adipogenic differentiation of BMSCs in vitro, and established an ovariectomized (OVX) osteoporosis model to test P2 × 7R activation on adipocytes formation, trabecular and cortical bone parameters in vivo. Our results showed that activation of P2 × 7R by BzATP resulted in increase in the gene expression of osteoblastic markers, the activity of alkaline phosphatase and bone mineralization, and decrease in the gene expression of adipogenic markers and the number of adipocytes generated by BMSCs. MicroCT analysis showed that BzATP treatment ameliorated the micro-architecture of trabecular bones in OVX mice, while cortical bone parameters were unaffected. H&E staining analysis showed that was increase in the volume of trabecular bone and number of trabecular bone, and decrease in bone marrow adipocytes in BzATP-treated OVX mice compared with OVX mice. Also, activation of P2 × 7R transduced to ERK1/2 and JNK signaling pathways. This transduction was prevented by BBG, U0126, and SP

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Adenosine TriphosphateAdipocytesAnimalsCell DifferentiationCells, CulturedDose-Response Relationship, DrugMaleMesenchymal Stem CellsOsteoblastsRats

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research